Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-9
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
ABCB1
Cancer name
Chronic Myelogenous Leukemia
Cancer site
Leukemia
Treatment type
Chemotherapy
Drug
Doxorubicin/Paclitaxel/Vincristine
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
Down
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
61
Male patients
38
Female patients
23
Age range and number
Not available
PMID
Description
Overexpression of miR-9 was sufficient to reverse cancer cell resistance to multiple chemotherapeutics in vitro and sensitized tumors to chemotherapy in vivo.
Tissue resource
peripheral blood from chronic myeloid leukemia patients
human chronic myelogenous leukemia cell lines K562
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
the First Affiliated Hospital of Dalian Medical University
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.